The Phase 1 Small Business Innovation Research grant from the NIH will be used to develop individual vaccines to stimulate immune responses that target the cicrcumsporozoite protein antigen of Plasmodium falciparum, the parasite responsible for most malaria-related deaths, according to PharmaLive.com.
The novel vaccines are to be used in a sequential regimen designed to induce the spectrum of immune responses needed for longer-lasting protection from the illness.
Protein Potential, the project’s leader, is tasked with producing the recombinant proteins required to produce cicrcumsporozoite protein antigens that can then be combined with adjuvants. Aduro BioTech plans to use its technology based on live-attenuated Listeria monocytogenes to create a strain that expresses cicrcumsporozoite protein antigen.
Together, the two vaccines will be used to stimulate both humoral and cellular immune responses, with the goal of creating a regimen that can be tested in human clinical trials.
“The partnership with Aduro is an exciting opportunity to explore the synergy of these two approaches to stimulate immunity and move rapidly to the clinic with a malaria vaccine,” Dr. B. Kim Lee Sim, the founder and president of Protein Potential, said, PharmaLive.com reports.